Are you Dr. Delioukina?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 51 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
8700 Beverly Blvd
West Hollywood, CA 90048Phone+1 310-423-1160Fax+1 310-423-4646
Summary
- Dr. Maria Delioukina, MD is an oncologist in West Hollywood, California. She is currently licensed to practice medicine in California. She is affiliated with Los Angeles General Medical Center and Huntington Health.
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
- Hennepin HealthcareResidency, Internal Medicine, 1995 - 1998
- St Petersburg Medical State AcademyClass of 1987
Certifications & Licensure
- CA State Medical License 1998 - 2025
Clinical Trials
- Zevalin-beam for Aggressive Lymphoma Start of enrollment: 2007 Jun 01
- Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
- KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Start of enrollment: 2012 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsFinal analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.Saad Z Usmani, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, Vladimir Vorobyev
Haematologica. 2022-10-01 - 8 citationsSwitching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.Maria-Victoria Mateos, Sophie Rigaudeau, Supratik Basu, Ivan Spicka, Rik Schots
Journal of Oncology Pharmacy Practice. 2023-07-01 - 157 citationsPhase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell LymphomaMark Kirschbaum, Paul Frankel, Leslie Popplewell, Jasmine Zain, Maria Delioukina
Journal of Clinical Oncology. 2011-03-20